Medical device company MicroPort CardioFlow has commercially launched its LBBOT Solution in Europe and Australia, following applicable regulatory clearances.
The LBBOT Solution is a portable real-time electrocardiogram (ECG) system designed to assist physicians during pacing procedures through continuous 12-lead ECG monitoring and automated ventricular activation timing measurements.
It’s a clinical assessment tool that supports procedural decision-making in pacing procedures, the company stated.
The system provides a continuous 12-lead ECG display with real-time V6 RWPT and V6–V1 interval measurements, helping clinicians optimise pacing procedures.
Amel Amblard, Vice-President Clinical Affairs – MicroPort CardioFlow, said, “LBBOT Solution reflects our commitment to advancing physiological pacing procedures through smarter, data-driven technologies. By combining automated measurements, continuous ECG visualization, and intuitive workflow integration, LBBOT Solution delivers reliable real-time insights that support procedural efficiency, consistency, and physician confidence.”
Designed to fit seamlessly into existing clinical workflows, the LBBOT Solution features a MicroPort CardioFlow Smart ECG device, Hookup Smart Software, and an RC115 cable. Its compact design and Bluetooth-enabled connectivity allow clinicians to access critical pacing information efficiently across multiple care settings, including electrophysiology labs, operating rooms, and outpatient centers.
According to the company, the system automates standardized measurements and delivers continuous beat-to-beat insights in real time, supporting procedural consistency and clinical decision-making.
Alongside the commercial rollout, the company is also conducting the LBBOT clinical study, an acute multicenter evaluation of implantation procedures. The study’s primary objective is to assess the Smart ECG system’s ability to monitor left bundle branch (LBB) success criteria by evaluating the proportion of investigators providing an overall favourable assessment of the system’s use in achieving Left Bundle Branch Area Pacing (LBBAP).
Secondary objectives include assessing device handling compared with standard electrophysiology systems.
A total of 55 patients were enrolled across six investigational sites in France and Spain, with patient enrollment completed in April 2026.
MicroPort CardioFlow, an associated company of the Chinese health care company MicroPort, specialises in structural heart intervention and rhythm management technologies.
